tiprankstipranks
Advertisement
Advertisement

PRQR Stock Latest News

ProQR: Buy Rating Reiterated as Axiomer Pipeline Progress and Upcoming Catalysts Support Unchanged $12 Price Target
RatingsProQR: Buy Rating Reiterated as Axiomer Pipeline Progress and Upcoming Catalysts Support Unchanged $12 Price Target
7d ago
PRQR
ProQR Posts Q1 2026 Results as Axiomer RNA Editing Pipeline Advances
PremiumCompany Announcements
ProQR Posts Q1 2026 Results as Axiomer RNA Editing Pipeline Advances
8d ago
6K
PRQR
ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position
PremiumCompany Announcements
ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position
8d ago
6K
PRQR
ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders
PremiumCompany Announcements
ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders
16d ago
6K
PRQR
ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase
PremiumCompany Announcements
ProQR Nominates Boehringer Ingelheim CMO Lykke Hinsch Gylvin to Board to Support Next Growth Phase
20d ago
6K
PRQR
ProQR Therapeutics management to meet with Cantor Fitzgerald
PremiumThe FlyProQR Therapeutics management to meet with Cantor Fitzgerald
1M ago
PRQR
ProQR Therapeutics management to meet with Oppenheimer
Premium
The Fly
ProQR Therapeutics management to meet with Oppenheimer
1M ago
PRQR
ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs
Premium
Company Announcements
ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs
1M ago
6K
PRQR
ProQR Partners with Ginkgo Bioworks, Launches AI Advisory Board to Drive Axiomer RNA Drug Discovery
PremiumCompany Announcements
ProQR Partners with Ginkgo Bioworks, Launches AI Advisory Board to Drive Axiomer RNA Drug Discovery
1M ago
6K
PRQR
Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy’ Stocks
PremiumStock Analysis & Ideas
Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy’ Stocks
2M ago
PRQR
SERV
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
PremiumCompany Announcements
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
2M ago
6K
PRQR
ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty
PremiumCompany Announcements
ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty
2M ago
PRQR
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
PremiumCompany AnnouncementsProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
2M ago
6K
PRQR
ProQR Therapeutics assumed with an Outperform at Oppenheimer
Premium
The Fly
ProQR Therapeutics assumed with an Outperform at Oppenheimer
2M ago
PRQR
ProQR Therapeutics reports FY25 EPS (EUR 0.40) vs (EUR 0.32) last year
Premium
The Fly
ProQR Therapeutics reports FY25 EPS (EUR 0.40) vs (EUR 0.32) last year
2M ago
PRQR
ProQR Therapeutics participates in a conf call hosted by Cantor Fitzgerald
PremiumThe Fly
ProQR Therapeutics participates in a conf call hosted by Cantor Fitzgerald
3M ago
PRQR
PRQR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
PRQR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
PRQR
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM
PremiumCompany Announcements
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM
3M ago
6K
PRQR
ProQR Therapeutics directors Dinko Valerio, Alison Lawton to depart
PremiumThe Fly
ProQR Therapeutics directors Dinko Valerio, Alison Lawton to depart
3M ago
PRQR
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans
PremiumCompany AnnouncementsProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans
4M ago
6K
PRQR
ProQR announces initial safety, PK data from Phase 1 trial of AX-0810
Premium
The Fly
ProQR announces initial safety, PK data from Phase 1 trial of AX-0810
4M ago
LLY
PRQR
Positive Outlook for ProQR’s AX-0810 in Treating Primary Sclerosing Cholangitis Justifies Buy Recommendation
Premium
Ratings
Positive Outlook for ProQR’s AX-0810 in Treating Primary Sclerosing Cholangitis Justifies Buy Recommendation
5M ago
PRQR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >